Randomized, Double-Blind, Placebo-Controlled, Single-Ascending-Dose Study of the Penetration of a Monoclonal Antibody Combination (ASN100) Targeting Staphylococcus aureus Cytotoxins in the Lung Epithelial Lining Fluid of Healthy Volunteers

• DOI: 10.1128/aac.00350-19
• Publication Date: 2019-05-23T13:30:03Z
• Authors: Zoltan Magyarics; Fraser Leslie; Johann Bartko; Harald Rouha; Steven Luperchio; Christian Schörge...; Michael Schwameis; Ulla Derhaschnig; Heimo Lagler; Leopold Stiebelle...; Christa Firbas; Susanne Weber; Ed Campanaro; Bernd Jilma; Eszter Nagy; Chris Stevens
• Keywords: Tolerability

ASN100 is a novel antibody combination of two fully human IgG1(κ) monoclonal antibodies (MAbs), ASN-1 and ASN-2, which neutralize six Staphylococcus aureus cytotoxins, alpha-hemolysin (Hla) five bicomponent leukocidins. We assessed the safety, tolerability, serum lung pharmacokinetics in randomized, double-blind, placebo-controlled single-dose-escalation first-in-human study.